¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low intensity void in proton flow"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • shielding proton
    Â÷Æó¾ç¼ºÀÚ
  • echo intensity
    ¸Þ¾Æ¸®°­µµ
  • high signal intensity
    °í½ÅÈ£°­µµ
  • isosignal intensity
    µî½ÅÈ£°­µµ
  • infectious intensity
    °¨¿°³óµµ, °¨¿°°­µµ
  • intensity
    °­µµ, ¼¼±â
  • intensity difference limen
    °­µµÆÇº°¹®Åΰª, °­µµÆÇº°¿ªÄ¡
  • intensity duration curve
    °­µµ±â°£°î¼±
  • intensity modulated radiation therapy
    °­µµº¯Á¶¹æ»ç¼±¿ä¹ý
  • maximum intensity projection
    ÃÖ´ë°­µµÅõ»ç
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • magnetic intensity
    ÀÚÀå°­µµ
  • radiant intensity
    ¹æ¿­°­µµ, ¹æ»ç°­µµ
  • signal intensity
    ½ÅÈ£°­µµ
  • low back pain
    Ç㸮ÅëÁõ, ¿äÅë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • low signal
    ¾àÇѽÅÈ£, Àú½ÅÈ£
  • blood flow velocity
    ÇÇÈ帧¼Óµµ, Ç÷·ù¼Óµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intensity difference limen
    °­µµÆÇº°¿ªÄ¡, °­µµÆÇº°¹®Åΰª
  • intensity modulated radiation therapy
    °­µµº¯Á¶¹æ»ç¼±¿ä¹ý
  • isosignal intensity
    µî½ÅÈ£°­µµ
  • magnetic intensity
    ÀÚÀå°­µµ
  • radiant intensity
    ¹æ¿­°­µµ, ¹æ»ç°­µµ
  • signal intensity
    ½ÅÈ£°­µµ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • maximum intensity projection
    ÃÖ´ë°­µµÅõ»ç
  • proton density contrast
    ¾çÀڹеµ´ëÁ¶
  • deshielded proton
    ¹ÌÂ÷Æó¾ç¼ºÀÚ
  • proton density
    ¾çÀڹеµ
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • free water proton
    ÀÚÀ¯¹°¾ç¼ºÀÚ
  • proton density weighted image
    ¾çÀڹеµ°­Á¶¿µ»ó
  • nonsaturated proton
    ºñÆ÷È­¾çÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • higher intensity
    °í°­µµ
  • intensity
    ¼¼±â, °­µµ(Ë­öô).
  • intensity
    ¼¼±â, °­µµ
  • intensity difference limen
    (À½ÀÇ)°­µµÆÇº°¿ªÄ¡
  • intensity difference thresheld
    °­µµÆÇº°(Ë­Óø÷÷ܬ)
  • intensity duration curve
    °­µµ±â°£°î¼±
  • intensity factor
    °­µµÀÎÀÚ
  • intensity level
    °­µµ¼öÁØ(Ë­öôâ©ñÞ).
  • intensity modulated radiation therapy
    °­µµº¯Á¶ ¹æ»ç¼±Ä¡·á
  • intensity of radiation
    ¹æ»ç¼±°­µµ
  • intensity of spectral lines
    ½ºÆåÆ®·³¼±ÀÇ °­µµ.
  • intensity of turbulence
    ¿Í·ùÀÇ °­µµ.
  • intensity variable
    °­µµº¯¼ö.
  • radiant intensity
    ¹æ»ç°­µµ(Û¯ÞÒË­öô).
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonsaturated proton
    ºñÆ÷È­ ¾çÀÚ
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • proton
    ¾ç¼ºÀÚ(åÕàõí­).
  • proton
    ¾ç¼ºÀÚ
  • proton (spin) density
    ¾çÀÚ ¹Ðµµ
  • proton MR spectroscopy
  • proton beam therapy
    ¾çÀÚ¼±Ä¡·á
  • proton density contrast
    ¾çÀÚ ¹Ðµµ ´ëÁ¶
  • proton density weighted image
    ¾çÀÚ ¹Ðµµ °­Á¶ ¿µ»ó
  • proton density weighting
    ¾çÀÚ °­Á¶
  • proton electron dipole dipole interaction
    ¾çÀÚ ÀüÀÚ ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£¹ÝÀÀ
  • proton radiation therapy
    ¾çÀÚ¼±Ä¡·á
  • proton relaxation
    ¾çÀÚ ÀÌ¿Ï
  • proton relaxation enhancement
    ¾çÀÚ ÀÌ¿Ï Áõ°­
  • proton shift
    ¾ç¼ºÀÚÀ̵¿(åÕàõí­ì¹ÔÑ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low background counter
    ³·Àº¹ÙÅÁ °è¼ö±â(ͪâ¦Ðï)
  • low-copy number
    Àú(î¸)Ä«ÇǼö(â¦)
  • low-density fraction
    Àú¹ÐµµºÐȹ(î¸ÚËÓøÝÂüñ)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • low-energy compound
    Àú(î¸)¿¡³ÊÁöÈ­ÇÕ¹°(ûùùêÚª)
  • low-energy electron diffraction
    Àú(î¸)¿¡³ÊÁö ÀüÀÚȸÀý(ï³í­üÞï¹)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • low-energy phophate acceptor
    Àú(î¸)¿¡³ÊÁö Àλê¼ö³³Ã¼(×òß«áôÒ¡ô÷)
  • low-frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ(î¸ÞºÓøû¡òõÓôìý)
  • low-level promoter
    ÀúÀ§(î¸êÈ) ÇÁ·Î¸ðÅÍ
  • low-lipid lipoprotein
    ÀúÁöÁú Áö´Ü¹éÁú(î¸ò·òõò·Ó±ÛÜòõ)
  • low-order antibody
    ÀúÂ÷Ç×ü(î¸ó­ù÷ô÷)
  • low-potential iron protein
    ÀúÀüÀ§ ö´Ü¹éÁú(î¸ï³êÈôÑÓ±ÛÜòõ)
  • low-quality protein
    ÀúÁú´Ü¹éÁú(î¸òõÓ±ÛÜòõ)
  • low-speed sedimentaion equilibrium
    Àú¼Óħ°­ÆòÇü(î¸áÜöØË½øÁû¬)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low back pain
    ¿äÅë
  • low echo area
    Àú¿¡ÄÚ±¸¿ª
  • low field MR scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • low pass filter
    ÀúÅë°ú¿©°ú±â
  • low signal
    Àú½ÅÈ£
  • ultra low field MR scanner
    ÃÊÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • echo intensity
    ¿¡ÄÚ°­µµ
  • high signal intensity
    °í½ÅÈ£°­µµ
  • higher intensity
    °í°­µµ
  • intensity
    ¼¼±â, °­µµ
  • isosignal intensity
    µî½ÅÈ£°­µµ
  • lower intensity
    Àú°­µµ
  • magnetic field intensity
    ÀÚÀå°­µµ
  • maximum intensity projection
    ÃÖ´ë°­µµÅõ»ç
  • peak intensity
    ÃÖ°í°­µµ, ÃÖ°í¼¼±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CL VOID clean voided specimen [urine]
LF labile factor; lactoferrin; laryngofissure; Lassa fever; latex fixation; left foot; left forearm; le...
LFD lactose-free diet; large for date [fetus]; late fetal death; lateral facial dysplasia; least fatal d...
LFT latex fixation test; latex flocculation test; left fronto-transverse [fetal position]; liver functio...
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PIXE Proton Induced X-ray Emission
PPI Proton Pump Inhibitor
PD Proton density
PMR Proton magnetic resonance
PMF Proton motive force
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • proton density contrast
    ¾çÀÚ ¹Ðµµ ´ëÁ¶
  • proton density weighting
    ¾çÀÚ °­Á¶
  • proton relaxation
    ¾çÀÚ ÀÌ¿Ï
  • proton spin density
    ¾çÀÚ ¹Ðµµ
  • radiant intensity
    ¹æ»ç °­µµ
  • sensory intensity
    Áõ»óÀÇ ÀÚ°¢µµ
  • tone intensity
    À½°­, ¼Ò¸®ÀÇ °­µµ, À½ÀÇ °­µµ
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ì Áõ»ó
    ¼ö¸éº´ ȯÀÚ¿¡°Ô¼­ º¼ ¼ö ÀÖ´Â ¼³ ÁøÀü.
  • low
    ³·Àº, Àú
  • low birth weight
    ÀúüÁß Ãâ»ý
  • low carat gold alloy
    ÀúÄ«¶óÆ® ±Ý ÇÕ±Ý
    16Ä«¶óÆ® ÀÌÇÏÀÇ ±Ý ÇÕ±Ý. ³³Âø ÇÕ±ÝÀ» ¸»ÇÑ´Ù.
  • low copper amalgam
    Àú µ¿ ¾Æ¸»°¨
  • low frequency
    ÀúÁÖÆÄ
    Á֯ļö°¡ ³·Àº ÆÄ. Áï, ÀüÀÚ±âÆÄÀÇ Á֯ļö¿¡ ÀÇÇÑ ºÐ·ù·Î¼­, º¸Åë 10 kHz ÀÌÇϸ¦ ¸»ÇÑ´Ù. ¿Àµð¿À
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄ Ä¡·á±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
proton ATPase <enzyme> An ion pump that actively transports hydrogen ions across lipid bilayers in exchange for ATP.
Major groups are the F-type ATPases, that run in reverse to synthesise ATP in bacterial, mitochondrial and chloroplast membranes (ATP synthase) and the V-type ATPases found in intracellular vesicles with an acidic lumen and on certain epithelial cells (e.g. Kidney intercalated cells). Gastric H/K ATPase is a proton ATPase.
(18 Nov 1997)
proton donor <chemistry> An acid, a susbstance that donates protons in an acid-base reduction reaction.
(10 Jan 1998)
proton-motive force Energy that is generated by the transfer of protons or electrons across an energy-transducing membrane and that can be used for chemical, osmotic, or mechanical work. Proton-motive force can be generated by a variety of phenomena including the operation of an electron transport chain, illumination of a purple membrane, and the hydrolysis of ATP by a proton atpase.
(12 Dec 1998)
proton pump Integral membrane proteins that transport protons across a membrane against a concentration gradient. This transport is driven by hydrolysis of ATP by hydrogen-transporting ATP synthase.
(12 Dec 1998)
proton pump inhibitor <pharmacology> A group of anti-ulcer medications which work by binding to H+/K+ ATPase, an enzyme which is found on the secretory surface of parietal cells. It thereby inhibits the final transport of hydrogen ions (via exchange with potasium) into the gastric lumen.
Examples of proton pump inhibitors include omeprazole and lansoprazole.
(27 Sep 1997)
average flow rate <physiology> The flow rate determined by dividing the total volume passed in a time period divided by the time period, usually quoted in mls per minute.
(05 Mar 2000)
Bingham flow The flow characteristics exhibited by a Bingham plastic.
(05 Mar 2000)
blood flow velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
(12 Dec 1998)
gene flow The movement of genes from one population to another viainterbreeding.
(09 Oct 1997)
maximal expiratory flow rate <chest medicine, physiology> Measurement of rate of airflow during the first liter expired after the first 200 ml have been exhausted during a forced vital capacity determination. Common abbreviations are MEFR, FEF 202-1200, and fef 0.2-1.2.
Acronym: MEFR
(21 Jun 2000)
maximal expiratory flow-volume curve <chest medicine> Curves depicting maximal expiratory flow in liters/second at each point of lung inflation (expressed in liters or percentage of forced vital capacity) during a forced vital capacity determination. Common abbreviation is mefv.
(12 Dec 1998)
maximal midexpiratory flow rate Measurement of rate of airflow over the middle half of a forced vital capacity determination (from the 25 percent level to the 75 percent level). Common abbreviations are mmfr and fef 25%-75%.
(12 Dec 1998)
renal blood flow, effective The amount of blood flowing to the parts of the kidney that are involved with the production of constituents of urine. It is that portion of the total renal blood flow that perfuses functional renal tissue (e.g., the glomeruli). It should be differentiated from renal plasma flow, effective which is based on the amount of plasma rather than on total renal blood.
(12 Dec 1998)
renal plasma flow <physiology> The amount of plasma that perfuses the kidneys per unit time, approximately 10% greater than effective renal plasma flow.
It should be differentiated from the renal blood flow which refers to the total volume of blood flowing through the renal vasculature, while the renal plasma flow refers to the rate of plasma flow.
(12 Dec 1998)
peak expiratory flow The maximum flow at the outset of forced expiration, which is reduced in proportion to the severity of airway obstruction, as in asthma.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • energy flow
    (»ýŰèÀÇ)¿¡³ÊÁö È帧
  • flow
    ¸Ó¸®Ä®ÀÌ ´Ã¾îÁö´Ù;(¹Ù¶÷¿¡)¾µ¸®´Ù;(Á¶¼ö°¡)¹Ð´Ù;¸¹ÀÌÀÖ´Ù;È帣°ÔÇÏ´Ù;¹ü¶÷½ÃŰ´Ù;È帧;À¯Ãâ·®;¹Ð¹°;È帣´Ù
  • flow diagram
    ÄÄÇ»ÅÍ ¹®Á¦Ã³¸®¸¦ À§ÇÑ ¼øÀ§Ç¥
  • flow line
    À¯¹®(È­¼º¾Ï À¯µ¿ ¶§¿¡ »ý±â´Â ÁÙ¹«´Ì)
  • flow sheet
    =FLOW DIAGRZM
  • low
    ³·Àº,³·°Ô,õÇϰÔ,(¼Ò°¡)¿ï´Ù
  • low-minded
    ºñ¿­ÇÑ
  • Low Church
    Àú±³È¸ÆÄ(¿µ±¹ ±¹±³ÆÄÁß,±³È¸ÀÇ ±³¸®,ÀǽĿ¡ ÁßÁ¡À» µÎÁö ¾Ê´Â ÇÑ ÆÄ)
  • Low Churchman
    Àú±³È¸ÆÄÀÇ »ç¶÷
  • Low Countries
    Áö±ÝÀÇ BeneluxÀÇ ÃÑĪ
  • Low Mass
    Æò¹Ì»ç
  • Low Sunday
    ºÎȰÀý ´ÙÀ½ÀÇ ÀÏ¿äÀÏ
  • Middle Low German
    Áß¼¼(Áß±â) ÀúÁö µ¶ÀϾî(12-15¼¼±â)
  • low
    ³·Àº;ÀúÁöÀÇ;Àú±ÞÇÑ;ħ¿ïÇÑ;°ª½Ñ;ÀûÀº;°Ë¼ÒÇÑ;ÀúÁ¶ÀÇ;ÀúÀ½ÀÇ;be in ~ water µ·¿¡ ±ÃÇÏ´Ù;bring ~ ¼èÅðÄÉ ÇÏ´Ù;ÁÙÀÌ´Ù
  • low
    ³·°Ô;³·Àº °÷¿¡;¾ßºñ(õ)ÇϰÔ;½Î°Ô;°Ë¼ÒÇÑ À½½ÄÀ¸·Î;Àûµµ °¡±îÀÌ;~ down ÈξÀ ¾Æ·¡¿¡;Ǫ´ëÁ¢ÇÏ¿©
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á